Touching Base Artificial Intelligence in the Emerald City and Targeting Colon Cancer Stem Cells
We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo. Then we discuss new research from University of California, San Diego, that used machine learning to identify networks of genes that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.
Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Uduak Thomas, GEN, October 6, 2025
AI in Protein Design: Hype vs. Reality Explained by David Baker
By Fay Lin, PhD, GEN, October 20, 2025
Nobel Anniversary: David Baker Keynotes STEM Fundraiser by ARCS Foundation Seattle
By Fay Lin, PhD, GEN, October 14, 2025
AI Treatment Reprograms and Triggers Cancer Stem Cells to Self-Destruct
GEN, October 20, 2025
The State of AI in Drug Discovery Registration
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
Hosted on Acast. See acast.com/privacy for more information.